Research programme: anti-infectives - Cengent Therapeutics
Alternative Names: ALF inhibitors research programme - Cengent Therapeutics; Zinc metalloprotease inhibitors - CengentLatest Information Update: 29 Aug 2007
At a glance
- Originator Cengent Therapeutics
- Class Small molecules
- Mechanism of Action Anthrax toxin inhibitors; Metalloprotease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Anthrax
Most Recent Events
- 29 Aug 2007 Discontinued - Preclinical for Anthrax in USA (unspecified route)
- 24 Nov 2003 Preclinical data from a media release have been added to the Bacterial Infections pharmacodynamics section
- 27 May 2003 Cengent Therapeutics' ALF inhibitors are available for licensing and further development (http://www.cengent.com)